Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial

被引:4
|
作者
Quintana-Hernandez, Domingo J. [1 ]
Rojas-Hernandez, Jaime [2 ]
Santana-Del Pino, Angelo [3 ]
Cespedes Suarez, Carmen [1 ]
Pellejero Silva, Monica [4 ]
Teresa Miro-Barrachina, Maria [5 ]
Ibanez Fernandez, Ignacio [5 ]
Estupinan Lopez, Jose Antonio [2 ]
Borkel, Lucas F. [6 ]
机构
[1] Atlantico Medio Univ, Dept Psychol, Tafira Baja, Spain
[2] Assoc Canaria Desarrollo Salud Traves Atenc, Las Palmas Gran Canaria, Spain
[3] Las Palmas de Gran Canaria Univ, Dept Math, Las Palmas Gran Canaria, Spain
[4] Atlantico Medio Univ, Dept Commun, Tafira Baja, Spain
[5] La Laguna Univ, Dept Clin Psychol Psychobiol & Methodol, San Cristobal la Laguna, Spain
[6] Assoc Cient Psicodel, Las Palmas Gran Canaria, Spain
关键词
Alzheimer's disease; cognitive stimulation; mindfulness; randomized clinical trial; relaxation; EPIDEMIOLOGY; DEMENTIA;
D O I
10.3233/JAD-220889
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: This longitudinal study addressed whether mindfulness practice prevents psychological and behavioral symptoms, especially mood disorders, in Alzheimer's disease (AD). Objective: To assess the incidence of depression in the course of AD and to determine which non-pharmacological treatment (NPT) is most effective in preventing psychopathological symptoms. Methods: We conducted a longitudinal, non-inferiority and equivalence randomized clinical trial, repeated-measures design, with a control group and three experimental treatments: mindfulness, cognitive stimulation, and relaxation. Each experimental group performed three weekly sessions for two years. The pharmacological treatment of all participants was donepezil (10 mg). Participants were patients with probable AD without diagnosed depression from the public neurology services of the Canary Health Service, Spain. Psychological evaluation was performed using the Geriatric Depression Scale (GDS), Hamilton Depression Rating Scale (HDRS), and Neuropsychiatric Inventory (NPI-Q). The statistical analysis included only patients who attended at least 75% of the sessions. A nonparametric, repeated-measures analysis was performed with Kruskal-Wallis H test and between-group differences with Mann-Whitney U test with Bonferroni correction (p < 0.008). Effect size was calculated with partial eta-squared. Results: The results showed significant differences with large effect sizes (eta(2)(p)>0.14) between mindfulness and the rest of the experimental groups as well as the control in the GDS, HDRS, and NPI-Q scales. Conclusion: Compared to the other experimental groups, only mindfulness prevented the onset of depression and other psychopathologies in early-stage AD. Based on its effectiveness in maintaining cognitive functions and preventing psychopathology, we recommend mindfulness as the first-choice NPT for mild to moderate AD.
引用
收藏
页码:471 / 481
页数:11
相关论文
共 50 条
  • [2] Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
    Egan, Michael F.
    Kost, James
    Tariot, Pierre N.
    Aisen, Paul S.
    Cummings, Jeffrey L.
    Vellas, Bruno
    Sur, Cyrille
    Mukai, Yuki
    Voss, Tiffini
    Furtek, Christine
    Mahoney, Erin
    Mozley, Lyn Harper
    Vandenberghe, Rik
    Mo, Yi
    Michelson, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (18): : 1691 - 1703
  • [3] Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial
    Jia, Yujie
    Zhang, Xuezhu
    Yu, Jianchun
    Han, Jingxian
    Yu, Tao
    Shi, Jiangwei
    Zhao, Lan
    Nie, Kun
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 17
  • [4] Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
    Yujie Jia
    Xuezhu Zhang
    Jianchun Yu
    Jingxian Han
    Tao Yu
    Jiangwei Shi
    Lan Zhao
    Kun Nie
    BMC Complementary and Alternative Medicine, 17
  • [5] Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial
    Howard, Robert
    Cort, Elizabeth
    Rawlinson, Charlotte
    Wiegand, Martin
    Downey, Anne
    Lawrence, Vanessa
    Banerjee, Sube
    Bentham, Peter
    Fox, Chris
    Harwood, Rowan
    Hunter, Rachel
    Livingston, Gill
    Moniz-Cook, Esme
    Panca, Monica
    Raczek, Malgorzata
    Ivenso, Chineze
    Russell, Gregor
    Thomas, Alan
    Wilkinson, Philip
    Freemantle, Nicholas
    Gould, Rebecca
    ALZHEIMERS & DEMENTIA, 2024, 20 (04) : 2990 - 2999
  • [6] Results of an open clinical trial of rivastigmine in mild and moderate Alzheimer's disease
    Dennler, HJ
    Retz, W
    Rösler, M
    PSYCHOPHARMAKOTHERAPIE, 2001, 8 (03): : 111 - 117
  • [7] Mindfulness in the Maintenance of Cognitive Capacities in Alzheimer's Disease: A Randomized Clinical Trial
    Quintana-Hernandez, Domingo J.
    Miro-Barrachina, Maria T.
    Ibanez-Fernandez, Ignacio J.
    Santana-del Pino, Angelo
    Quintana-Montesdeoca, Maria P.
    Rodriguez-de Vera, Bienvenida
    Morales-Casanova, David
    del Carmen Perez-Vieitez, Maria
    Rodriguez-Garcia, Javier
    Bravo-Caraduje, Noelia
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 50 (01) : 217 - 232
  • [8] Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease
    Knopman, David S.
    COGNITIVE AND BEHAVIORAL NEUROLOGY, 2008, 21 (04) : 197 - 201
  • [9] Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe
    Feldman, H. H.
    Doody, R. S.
    Kivipelto, M.
    Sparks, D. L.
    Waters, D. D.
    Jones, R. W.
    Schwam, E.
    Schindler, R.
    Hey-Hadavi, J.
    DeMicco, D. A.
    Breazna, A.
    NEUROLOGY, 2010, 74 (12) : 956 - 964
  • [10] The Feasibility of a Mindfulness Intervention for Depression in People with Mild Dementia: A Pilot Randomized Controlled Trial
    Noone, Deirdre
    Payne, Jacob
    Stott, Josh
    Aguirre, Elisa
    Patel-Palfreman, Ms Mina
    Stoner, Charlotte
    Hanrachtaigh, Eanna O.
    Spector, Aimee
    CLINICAL GERONTOLOGIST, 2023, 46 (03) : 346 - 358